• head_banner_01

2022 New Style Polar Amino Acids - Desmopressin Acetate to Treat central Diabetes Insipidus – Gentolex

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

We support our prospective buyers with ideal top quality merchandise and superior level provider. Becoming the specialist manufacturer in this sector, we have now attained abundant practical expertise in producing and managing for 1 2-Dimethylimidazole, Stearate Soap, 2-Hydroxy-1-Naphthaldehyde, We have been in procedure for more than 10 years. We're dedicated to excellent solutions and consumer aid. We invite you to definitely pay a visit to our business for a personalized tour and advanced small business guidance.
2022 New Style Polar Amino Acids - Desmopressin Acetate to Treat central Diabetes Insipidus – Gentolex Detail:

Product Detail

Name  Desmopressin
CAS number  16679-58-6
Molecular formula  C46H64N14O12S2
Molecular weight  1069.22
EINECS Number  240-726-7
Specific rotation  D25 +85.5 ± 2° (calculated for the free peptide)
Density  1.56±0.1 g/cm3(Predicted)
RTECS No.  YW9000000
Storage conditions  Store at 0°C
Solubility  H2O:soluble20mg/mL, clear, colorless
Acidity coefficient  (pKa) 9.90±0.15 (Predicted)

Synonyms

MPR-TYR-PHE-GLN-ASN-CYS-PRO-D-ARG-GLY-NH2; MINIRIN; [DEAMINO1, DARG8] VASOPRESSIN; [DEAMINO-CYS1, D-ARG8]-VASOPRESSIN; DDAVP, HUMAN; DESMOPRESSIN; DESMOPRESSIN, HUMAN; DESAMINO-[D-ARG8] VASOPRESSIN

Indications

(1) Treatment of central diabetes insipidus. After the drug can reduce urinary excretion, reduce urinary frequency and reduce nocturia.

(2) Treatment of nocturnal enuresis (patients aged 5 years or older).

(3) Test the renal urine concentration function, and carry out the differential diagnosis of renal function.

(4) For hemophilia and other bleeding diseases, this product can shorten the bleeding time and prevent bleeding. It can reduce the amount of intraoperative blood loss and postoperative oozing; especially in conjunction with reasonably controlled blood pressure during surgery, it can reduce intraoperative bleeding from different mechanisms, and reduce postoperative oozing, which can play a better role in blood protection.

Treatment of diabetes insipidus

Diabetes insipidus is primarily a disorder of water metabolism characterized by excess urine output, polydipsia, hypoosmolarity, and hypernatremia. Partial or complete deficiency of vasopressin (central diabetes insipidus), or renal insufficiency of vasopressin (nephrogenic diabetes insipidus) can be onset. Clinically, diabetes insipidus is similar to primary polydipsia, a condition in which excessive fluid intake is caused by a malfunction of the regulatory mechanism or abnormal thirst. Contrary to primary polydipsia, the increase in water intake in patients with diabetes insipidus is a corresponding response to changes in osmotic pressure or blood volume.


Product detail pictures:

2022 New Style Polar Amino Acids - Desmopressin Acetate to Treat central Diabetes Insipidus – Gentolex detail pictures

2022 New Style Polar Amino Acids - Desmopressin Acetate to Treat central Diabetes Insipidus – Gentolex detail pictures


Related Product Guide:

Sticking to the principle of "Super Quality, Satisfactory service" ,We are striving to be a good business partner of you for 2022 New Style Polar Amino Acids - Desmopressin Acetate to Treat central Diabetes Insipidus – Gentolex , The product will supply to all over the world, such as: Afghanistan, Turkey, Nairobi, Adhering to the management tenet of "Managing Sincerely, Winning by Quality", we try our best to provide excellent products and service to our clients. We look forward to making progress together with domestic and international clients.
  • This company can be well to meet our needs on product quantity and delivery time, so we always choose them when we have procurement requirements.
    5 Stars By Lorraine from Uganda - 2017.08.21 14:13
    As a veteran of this industry, we can say that the company can be a leader in the industry, select them is right.
    5 Stars By Debby from Swiss - 2017.05.02 18:28
    Write your message here and send it to us